Aroa Biosurgery Ltd
ASX:ARX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.44
0.87
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ARX stock under the Base Case scenario is 1.083 AUD. Compared to the current market price of 0.655 AUD, Aroa Biosurgery Ltd is Undervalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aroa Biosurgery Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ARX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Aroa Biosurgery Ltd
Balance Sheet Decomposition
Aroa Biosurgery Ltd
Current Assets | 69m |
Cash & Short-Term Investments | 30.2m |
Receivables | 28.9m |
Other Current Assets | 9.9m |
Non-Current Assets | 42m |
PP&E | 22.2m |
Intangibles | 19.7m |
Other Non-Current Assets | 104k |
Current Liabilities | 9.5m |
Accounts Payable | 3.7m |
Accrued Liabilities | 3.7m |
Other Current Liabilities | 2.1m |
Non-Current Liabilities | 6.6m |
Long-Term Debt | 6.4m |
Other Non-Current Liabilities | 174k |
Earnings Waterfall
Aroa Biosurgery Ltd
Revenue
|
69.1m
NZD
|
Cost of Revenue
|
-10.1m
NZD
|
Gross Profit
|
59m
NZD
|
Operating Expenses
|
-69.6m
NZD
|
Operating Income
|
-10.7m
NZD
|
Other Expenses
|
43k
NZD
|
Net Income
|
-10.6m
NZD
|
Free Cash Flow Analysis
Aroa Biosurgery Ltd
NZD | |
Free Cash Flow | NZD |
ARX Profitability Score
Profitability Due Diligence
Aroa Biosurgery Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Aroa Biosurgery Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
ARX Solvency Score
Solvency Due Diligence
Aroa Biosurgery Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Aroa Biosurgery Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARX Price Targets Summary
Aroa Biosurgery Ltd
According to Wall Street analysts, the average 1-year price target for ARX is 0.951 AUD with a low forecast of 0.72 AUD and a high forecast of 1.103 AUD.
Dividends
Current shareholder yield for ARX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ARX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
Contact
IPO
Employees
Officers
The intrinsic value of one ARX stock under the Base Case scenario is 1.083 AUD.
Compared to the current market price of 0.655 AUD, Aroa Biosurgery Ltd is Undervalued by 39%.